|
KMID : 0361020230660080505
|
|
Korean Journal of Otolaryngology - Head and Neck Surgery
2023 Volume.66 No. 8 p.505 ~ p.513
|
|
|
Drug Repositioning for Treatment of Head and Neck Cancers
|
|
Kwon Min-Su
|
|
|
Abstract
|
|
|
|
Head and neck cancer (HNC) is a complex disease that poses significant therapeutic challeng-es. Traditional treatment options such as surgery, radiation, and chemotherapy have limitedefficacy and often result in significant side effects. In recent years, drug repositioning hasemerged as a promising strategy to identify new therapeutic options for HNC. Drug reposi-tioning involves repurposing existing drugs, already approved for other indications, for thetreatment of HNC. This approach takes advantage of existing knowledge about drug safetyand efficacy, reducing the time and cost needed to develop new drugs. By leveraging theknown safety profiles, pharmacokinetic, and pharmacodynamic properties of these drugs,drug repositioning can accelerate the drug development process and reduce costs. In this re-view, the current status of drug repositioning efforts for HNC and the challenges and opportu-nities associated with this approach are discussed. We also highlight some of the most promis-ing drug candidates that have emerged from recent studies and clinical trials. Overall, drugrepositioning has the potential to significantly improve the treatment landscape for HNC andoffer new hope for patients with this challenging disease.
|
|
|
KEYWORD
|
|
|
Combination drug therapy, Drug repositioning, Head and neck cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|